Clinical trials: C-KIT Mutation
Asian Patients With Advanced Gastro-intestinal Stromal Tumors (GIST) Treated With Imatinib
A Retrospective Study of C-kit Mutation Status in Asian Patients With Advanced Gastro-intestinal Stromal Tumors (GIST) Treated With Imatinib.
Imatinib is the current standard treatment for advanced GIST. Previous studies have shown that GIST genotype was associated with treatment outcomes with exon 11 having superior outcome compared with exon 9 or WT.10, 11 In…
- Trial name
- NCT01227746
- Testing
- Tumor biopsies
- Where
- Singapore
- Sponsor
- National University Hospital, Singapore
Melanoma
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
The purpose of this study is to determine whether nilotinib is efficacious in the treatment of metastatic and/or inoperable melanoma harboring a c-Kit mutation.
- Trial name
- TEAM (NCT01028222)
- Testing
- Nilotinib, DTIC
- Where
- 49 sites in United States, Argentina and 12 more
- Volunteers
- 55 people
- Sponsor
- Novartis Pharmaceuticals
GIST, Malignant, KIT Exon 13 Mutation
POETIG Trial - POnatinib After rEsisTance to Imatinib in GIST
This is a non-randomized, open-label, multicenter phase 2 study to evaluate the efficacy and safety of ponatinib in patients with metastatic and/or unresectable GIST after prior failure or intolerability of imatinib.
- Conditions
- GIST, Malignant, KIT Exon 13 Mutation, KIT Gene Mutation
- Trial name
- POETIG (NCT03171389)
- Testing
- Ponatinib 30 MG
- Where
- Germany
- Volunteers
- 81 people
- Sponsor
- Sebastian Bauer
Metastatic Melanoma
Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit
The objective is to assess the efficacy and safety of masitinib at 7.5 mg/kg/day in the treatment of patients with non-resectable or metastatic stage 3 or stage 4 melanoma carrying a mutation in the juxta membrane domain of c-Kit…
- Trial name
- NCT01280565
- Testing
- Masitinib, Dacarbazine
- Where
- 9 sites in United States, Czechia and 5 more
- Volunteers
- 134 people
- Sponsor
- AB Science
Relapsed AML, T(8;21)
Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation
In this multi-center, open-label, no control,prospective clinical trial, a total of 30 relapsed acute myeloid leukemia with t(8;21) translocation and KIT D816 mutation patients will be enrolled.
- Conditions
- Relapsed AML, T(8;21), C-KIT Mutation
- Trial name
- NCT03560908
- Testing
- Dasatinib
- Where
- China
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Myeloid Leukemia
Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML
To assess the efficacy of tyrosine-kinase inhibitor midostaurin in c-KIT or FLT3-ITD mutated t(8;21) AML. To assess the efficacy of midostaurin depending on the type of c-KIT mutation
- Trial name
- MIDOKIT (NCT01830361)
- Testing
- midostaurin (PKC412)
- Where
- 10 sites in Germany
- Volunteers
- 18 people
- Sponsor
- Technische Universität Dresden
Full Gene Sequences of c-KIT、PDGFRA and DOG1 Are Analyzed With the Screening-sequencing Approach, Investigate the Characteristics and Variations Associated With the Different Gene Mutations of c-KIT、PDGFRA and DOG1 in GIST Patients
Study on the Evolution of Genes Mutation Related With Gastrointestinal Stromal Tumors
Mutations of tumor-related genes are dynamic. Gastrointestinal stromal tumor cells often are obviously more invasive in case of recurrence.
- Trial name
- NCT01505205
- Volunteers
- 60 people
- Sponsor
- Guangxi Medical University
Acute Myeloid Leukemia With T(8;21)(Q22;Q22), Acute Myeloid Leukemia With T(16;16)(P13;Q22)
A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia
The goal of this clinical trial is to learn if avapritinib combined with standard induction therapy works to treat newly diagnosed adult acute myeloid leukemia (AML) patients with KIT mutations and t(8;21)(q22;q22.1)…
- Conditions
- Acute Myeloid Leukemia With T(8;21)(Q22;Q22), Acute Myeloid Leukemia With T(16;16)(P13;Q22), KIT Gene Mutation, Avapritinib
- Trial name
- NCT07028073
- Testing
- Group A (FIT): Avapritinib + IA regimen, Group B (UNFIT): Avapritinib + VA regimen
- Where
- China
- Volunteers
- 78 people
- Sponsor
- The First Affiliated Hospital of Soochow University
GIST - Gastrointestinal Stromal Tumor, KIT Gene Mutation
Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment
Gastrointestinal stromal tumors (GISTs) are mostly driven by c-kit or PDGFRA mutations, and commonly occur in the stomach and small intestine.
- Trial name
- NCT07559864
- Testing
- physician-selected treatment, Regorafenib + Envafolimab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Jian Li
Mastocytosis
Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation
The objective is to compare efficacy and safety of AB1010 at 3 or 6 mg/kg/day in treatment of patients with mastocytosis with handicap and bearing activating point mutations in the phosphotransferase domain of c-Kit such as the…
- Trial name
- NCT01266369
- Testing
- masitinib
- Volunteers
- 21 people
- Sponsor
- AB Science
Mastocytosis
Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis
This is a 12 weeks study aimed at assessing the safety and efficacy of 2 doses of AB1010 in patients suffering from indolent systemic mastocytosis with handicap.
- Trial name
- NCT00831974
- Testing
- masitinib (AB1010)
- Volunteers
- 23 people
- Sponsor
- AB Science
AML, Childhood, Relapse/Recurrence
Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation
The purpose of this study is to evaluate the efficacy and safety of avapritinib in relapsed or refractory pediatric core binding factor acute myeloid leukemia with KIT mutation.
- Conditions
- AML, Childhood, Relapse/Recurrence, Refractory AML, Core Binding Factor Acute Myeloid Leukemia
- Trial name
- NCT06316960
- Testing
- Avapritinib, Azacitidine Injection, Decitabine Injection
- Where
- 12 sites in China
- Volunteers
- 50 people
- Sponsor
- Children's Hospital of Soochow University
Mastocytosis
Molecular Mechanisms and Diagnosis of Mastocytosis
Mastocytosis is a disorder characterized by presence of excessive numbers of mast cells in skin, bone marrow and internal organs.
- Trial name
- NCT00336076
- Testing
- Collection of blood and bone marrow
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- University of Michigan
Metastatic Melanoma
Trial of Imatinib (Gleevec®) in Selected Patients With Metastatic Melanoma
This study is a single-armed, open-label, single-center phase II trial of signal transduction inhibitor number 571 (STI-571) systemic therapy in selective patients with metastatic melanoma, and aims to study the efficacy and…
- Trial name
- NCT00881049
- Testing
- Imatinib (Gleevec)
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Peking University
C-KIT Mutation
A Study of c-Kit Mutation as MRD in Acute Myeloid Leukemia
C-Kit is involved in an essential pathway of disease occurrence and is closely related to the poor prognosis of patients. However, the clinical significance of c-Kit mutation as molecular MRD monitoring is still unclear.
- Trial name
- NCT06116318
- Where
- China
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Sarcoma, Gastrointestinal Stromal Tumors
Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation
The presence of c-kit mutation is an independent poor prognostic factor for relapse in addition to large size (> 5 cm) and high mitotic rate (> 5/50 high power field [HPF]) in localized gastrointestinal stromal tumor (GIST)…
- Trial name
- NCT00278876
- Testing
- Imatinib mesylate (Glivec)
- Where
- 4 sites in South Korea
- Volunteers
- 47 people
- Sponsor
- Asan Medical Center
Gastrointestinal Stromal Tumors, Resected Gastrointestinal Stromal Tumors
Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)
This is a 2 arms study concerning patients with primary GIST who followed an Imatinib adjuvant treatment for 3 years after surgery and who have a high risk of recurrence.
- Conditions
- Gastrointestinal Stromal Tumors, Resected Gastrointestinal Stromal Tumors, Non-metastatic, High Risk of Recurrence
- Trial name
- ImadGist (NCT02260505)
- Testing
- Imatinib maintenance
- Where
- 17 sites in France
- Volunteers
- 136 people
- Sponsor
- Centre Leon Berard
Leukemia
Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia
The purpose of this study was to determine the efficacy and safety of twice daily (bid) oral midostaurin in patients with Aggressive Systemic Mastocytosis (ASM) or Mast Cell Leukemia (MCL) with or without an Associated…
- Trial name
- NCT00782067
- Testing
- Midostaurin (PKC412)
- Where
- 29 sites in United States, Australia and 10 more
- Volunteers
- 116 people
- Sponsor
- Novartis Pharmaceuticals
Indolent Systemic Mastocytosis
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment
The purpose of this study is to evaluate the efficacy and safety of oral masitinib versus placebo in the treatment of patients suffering from smouldering or indolent systemic mastocytosis with severe symptoms of mast cell…
- Trial name
- NCT04333108
- Testing
- Masitinib, Best Supportive Care
- Where
- 17 sites in France, Germany and 6 more
- Volunteers
- 140 people
- Sponsor
- AB Science
Gastrointestinal Stromal Tumour (GIST)
Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation
The main purpose of this study is to examine whether regorafenib treatment can help people with gastrointestinal stromal tumours (GIST) and have gene mutation on c-kit exon 17. The safety of regorafenib treatment is also examined.
- Trial name
- NCT02606097
- Testing
- regorafenib
- Where
- Taiwan
- Volunteers
- 19 people
- Sponsor
- Chang Gung Memorial Hospital